The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Viridian Therapeutics Inc shares valued at $117,050 were purchased by Beetham Thomas W. on Sep 27 ’24. At $23.41 per share, Beetham Thomas W. acquired 5,000 shares. The insider’s holdings grew to 6,000 shares worth approximately $0.15 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Mahoney Stephen F. purchased 21,400 shares, netting a total of over 499,262 in proceeds. Following the buying of shares at $23.33 each, the insider now holds 21,400 shares.
Before that, Fairmount Funds Management LLC had added 1,600,000 shares to its account. In a trade valued at $30,000,000, the Director bought Viridian Therapeutics Inc shares for $18.75 each. Upon closing the transaction, the insider’s holdings increased to 1,600,000 shares, worth approximately $83.56 million.
As published in a research note from Needham on September 11, 2024, Viridian Therapeutics Inc [VRDN] has been retained to a Buy and the price target has been revised to $38. Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid June. As of June 06, 2024, Goldman has initiated its “Buy” rating for VRDN. Earlier on May 09, 2024, Ladenburg Thalmann downgraded its rating. Their new recommendation was “a Neutral” for VRDN stock which previously was a “a Buy”.
Analyzing VRDN Stock Performance
During the last five days, there has been a surge of approximately 13.32%. Over the course of the year, Viridian Therapeutics Inc shares have jumped approximately 11.34%. Shares of the company reached a 52-week high of $24.68 on 10/02/24 and a 52-week low of $11.40 on 06/04/24. A 50-day SMA is recorded $17.50, while a 200-day SMA reached $16.82. Nevertheless, trading volume fell to 0.93 million shares from 2.47 million shares the previous day.
Support And Resistance Levels for Viridian Therapeutics Inc (VRDN)
According to the 24-hour chart, there is a support level at 23.48, which, if violated, would cause prices to drop to 22.70. In the upper region, resistance lies at 24.85. The next price resistance is at 25.45. RSI (Relative Strength Index) is 73.07 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.30, which suggests the price will increase in the coming days. Percent R is at 9.98%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
